• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

GenVivo, Inc.

Monday, June 03, 2024
CP
Oncology
GenVivo was founded on the idea that we can effectively treat cancer patients with the latest gene delivery technologies. We are committed to enhancing the overall patient treatment experience. We deliver innovative drugs to empower the patient’s own immune system to mount a targeted attack against cancer. These therapies are off-the-shelf and come without the cost and time delays associated with personalized cancer vaccines. We are dedicated to providing accessible and efficient solutions that redefine the landscape of cancer treatment. GenVivo is a fully-integrated. clinical stage company with in-house cGMP manufacturing for clinical drug product. Our lead candidate, GEN2, is in Phase I trials.
GenVivo, Inc.
Company Website: https://genvivoinc.com/
Lead Product in Development: GEN2: IV administered, highly engineered vector encoding proprietary pro-drug facilitated cancer killing and immunocytokine genes.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 4

Website

https://genvivoinc.com/

Company HQ City

San Marino

Company HQ State

CA

Company HQ Country

United States

CEO/Top Company Official

David H. Dornsife

Lead Product in Development

GEN2: IV administered, highly engineered vector encoding proprietary pro-drug facilitated cancer killing and immunocytokine genes.

Development Phase of Primary Product

Phase I
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS